Mastodon Skip to main content

Posts

Showing posts with the label BI 1819479

Boehringer Ingelheim has submitted the IND application for BI 1819479 in China

 Boehringer Ingelheim filed an IND application for BI 1819479, an ATX inhibitor that inhibits lysophospholipase. The US FDA granted an Orphan Drug Designation to BI 1819479 for the treatment of idiopathic pulmonary fibrosis in November 2023. BI 1819479 Boehringer Ingelheim has completed the  phase 1 trials of BI 1819479 in healthy participants. In 2024,  Boehringer Ingelheim initiated the phase 2 trial in patients with Idiopathic Pulmonary Fibrosis (IPF). The study consists of 3 doses and 1 placebo group, aiming to enroll 300 patients. Annual rate of decline in Forced Vital Capacity (FVC) is the primary endpoint. As stated by  Boehringer Ingelheim , BI 1819479 is an investigational compound that may address pulmonary fibrosis—a scarring of the lung tissue that negatively impacts lung function—associated with IPF, a type of interstitial lung disease. And, the FDA granted Orphan Drug Designation to BI 1819479 based on the availability of preclinical data. Metabolic effects of the ATX-LPA